Exacerbation of cataplexy following gradual withdrawal of antidepressants: Manifestation of probable protracted rebound cataplexy

Sleep Medicine

Volumn 10, Issue 4, 2009, Pages 416-421

  Ristanovic, Ruzica K ^a   Liang, Howard ^b   Hornfeldt, Carl S ^c   Lai, Chinglin ^d  

^a EVANSTON HOSPITAL   (United States)

^b Eagle Creek Research Solutions   (United States)

^c Inc ^*  (United States)

^d JAZZ PHARMACEUTICALS   (United States)

Author keywords

Gradual withdrawal of anticataplectic drugs; Narcolepsy; Rebound cataplexy; Safety; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; OXYBATE SODIUM; PAROXETINE; PLACEBO; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; CATAPLEXY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ENURESIS; HUMAN; MAJOR CLINICAL STUDY; NARCOLEPSY; NAUSEA; PRIORITY JOURNAL; REBOUND CATAPLEXY; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CATAPLEXY; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NARCOLEPSY; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SODIUM OXYBATE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 67349249105     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2008.04.004     Document Type: Article

References (27)

1. Akimoto H., Honda Y., and Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 21 (1960) 704-706
2. Houghton W.C., Scammell T.E., and Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 8 (2004) 355-366
3. Scammell T.E. The neurobiology, diagnosis and treatment of narcolepsy. Ann Neurol 53 (2003) 154-166
4. Nishino S., and Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52 (1997) 27-78
5. Chen C.N. The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad Med J 56 Suppl. 1 (1980) 86-89
6. Wing Y.K., Lee S., Chiu H.F., Ho C.K., and Chen C.N. A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine. Postgrad Med J 70 (1994) 34-36
7. Smith M., Parkes J.D., and Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 5 Suppl. 1 (1996) 217
8. Guilleminault C., Mancuso J., Salva M.A., et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 9 1 Pt. 2 (1986) 275-279
9. Larrosa O., de la Llave Y., Bario S., Granizo J.J., and Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 24 (2001) 282-285
10. Kratochvil C.J., Vaughan B.S., Harrington M.J., and Burke W.J. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 4 (2003) 1165-1174
11. Guilleminault C., Raynal D., Takahashi S., Carskadon M., and Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 54 (1976) 71-87
12. Martinez-Rodriguez J., Iranzo A.S.J., Genis D., Molins A., Silva Y., and Melendez R. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 17 (2002) 113-116
13. Parkes J.D., and Schachter M. Clomipramine and clonazepam in cataplexy. Lancet 2 (1979) 1085-1086
14. Schachter M., and Parkes J.D. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 43 (1980) 171-174
15. Langdon N., Shindler J., Parkes J.D., and Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 9 (1986) 371-373
16. Scharf M.B., and Fletcher K. Rebound cataplexy, a complication of drug withdrawal in narcolepsy. Sleep Res 17 (1988) 246
17. Poryazova R., Siccoli M., Werth E., and Bassetti C.L. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 65 (2005) 967-968
18. Ristanovic R.K. Severity of rebound cataplexy is worse following the discontinuation of tricylic antidepressants (TCAs) than selective serotonin reuptake inhibitors (SSRIs). Sleep 29 Suppl. (2006) A219-A220
19. ® International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21.
20. ® International Study Group. A double-blind, placebo-controlled, study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:289-95.
21. American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine; 2001.
22. Gelb M., Guilleminault C., Kraemer H., et al. Stability of cataplexy over several months-information for the design of therapeutic trials. Sleep 17 (1994) 265-273
23. Hublin C. Narcolepsy. Current drug treatment options. CNS Drugs 5 (1996) 426-436
24. Vignatelli L., D'Alessandro R., and Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev 3 (2005) CD003724
25. ® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9.
26. ® Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23.
27. ® Multicenter Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003;41:131-5.